A new AAT decision handed down in December 2023 (Active Sports Management Pty Ltd and Industry Innovation and Science Australia) has found that activities in respect of development of a customised basketball shoe were not eligible under the R&D Tax Incentive. Background points from the case include: Active Sports Management Pty Ltd, the applicant, carries out a business which includes importing and selling sports apparel, footwear, accessories, hoodies, and tracksuits, among other things. It also designs and develops products for the […]
The 2023‑24 Mid‑Year Economic and Fiscal Outlook (MYEFO) was released by the Government in December 2023. New estimates within MYEFO show the R&D Tax Incentive (‘RDTI’) is expected to cost an extra $2.1 billion over the next four years, including an additional $432 million in FY22-23. According to the report, the increase is being driven primarily by claims arising from biomedicine, artificial intelligence, and machine learning activities. It’s part of a growing trend: software claims accounted for 30% of RDTI […]
On 15 December 2023, the ATO has released two new taxpayer alerts: Taxpayer Alert TA 2023/4 Research and development activities delivered by associated entities. This relates to arrangements identified by the ATO where an entity incorrectly claims the R&D tax offset for expenditure incurred under an agreement with an associated entity who conducts those activities. Taxpayer Alert TA 2023/5 Research and development activities conducted overseas for foreign related entities outlines ATO concerns about arrangements where Australian entities claim the R&D tax offset for […]
Over recent months, a number of companies have reported to the ASX receipt of substantial Refundable R&D Tax Offsets. Notable receipts include: Syntara Limited (ASX: SNT) reported a $5.25 million Refundable R&D tax offset related to its clinical development pipeline including PXS-5505 in myelofibrosis project; Neurotech International (ASX: NTI) reported a $3.17 million Refundable R&D tax offset related to its development of treatments for paediatric neurological disorders ClearVue Technologies Limited (ASX:CPV) reported a $0.94 million Refundable R&D tax offset related […]